Trial: 202102066

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects

Phase

III (Cancer Control)

Principal Investigator

Kahl, Brad

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov